Source:
"This was the key figure in a Nature Medicine paper published on Dec 14, 2021. It showed clearly that myocarditis after vaccination (in this case, Moderna dose two) was higher than myocarditis after sars-cov-2 infection for people <40.
... While the denominator for vaccines is known with precision, the true number of infections is unknown.
Many people don’t seek testing or medical care.
So the red bar above will be shorter if you used a sero-prevalence (aka the correct) denominator.
The authors needed to fix this.
The other problem is that this analysis lumps together men & women, while men have the greatest risk.
Well, the authors are back with a new pre-print to fix this point, and here is what they find.
Many people don’t seek testing or medical care.
So the red bar above will be shorter if you used a sero-prevalence (aka the correct) denominator.
The authors needed to fix this.
The other problem is that this analysis lumps together men & women, while men have the greatest risk.
Well, the authors are back with a new pre-print to fix this point, and here is what they find.
It is now clear for men <40, dose two and dose three of Pfizer have more myocarditis than sars-cov-2 infection, and this is true for dose one and dose two of Moderna.
Pfizer boosters (Dose three) have more myocarditis for men <40 than infection.
Myocarditis post infection is more common as you get older, in contrast with myocarditis post vaccination, which is more common as you are younger (reverse gradients)
... If the authors fixed the denominator for viral infection (i.e. used sero-prevalance), it would look even worse
If the authors separate men 16-24 from 12-15 and 25-40, it would likely look worst in 16-24 age group.
But regardless, these findings already clearly dispel the true misinformation online: ... vaccines can have risks of myocarditis exceeding risks of myocarditis from infection.
Please stop saying otherwise.
And here is why it matters:
There is marked uncertainty as to whether dose three actually lowers severe outcomes & hospitalizations in young men.
The FDA is making a huge regulatory gamble with boosters, and they are cheered on by many who are not adept at data analysis.
Boosting 16-40 year old men might not be in their best interest (it might be net detrimental).
We simply do not know with confidence. ...
... The US FDA must halt use of Moderna in Men <40, as other nations have.
... people needlessly suffer due to their inaction.
... Perhaps that is why Marion Gruber and Phil Krause, the Director and Deputy Director of vaccine products at FDA, resigned: they wanted no part of this."
Dr. Vinay Prasad is a hematologist-oncologist and Associate Professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco. He runs the VKPrasad lab at UCSF, which studies cancer drugs, health policy, clinical trials and better decision making. He is author of over 300 academic articles, and the books Ending Medical Reversal (2015), and Malignant (2020).
Pfizer boosters (Dose three) have more myocarditis for men <40 than infection.
Myocarditis post infection is more common as you get older, in contrast with myocarditis post vaccination, which is more common as you are younger (reverse gradients)
... If the authors fixed the denominator for viral infection (i.e. used sero-prevalance), it would look even worse
If the authors separate men 16-24 from 12-15 and 25-40, it would likely look worst in 16-24 age group.
But regardless, these findings already clearly dispel the true misinformation online: ... vaccines can have risks of myocarditis exceeding risks of myocarditis from infection.
Please stop saying otherwise.
And here is why it matters:
There is marked uncertainty as to whether dose three actually lowers severe outcomes & hospitalizations in young men.
The FDA is making a huge regulatory gamble with boosters, and they are cheered on by many who are not adept at data analysis.
Boosting 16-40 year old men might not be in their best interest (it might be net detrimental).
We simply do not know with confidence. ...
... The US FDA must halt use of Moderna in Men <40, as other nations have.
... people needlessly suffer due to their inaction.
... Perhaps that is why Marion Gruber and Phil Krause, the Director and Deputy Director of vaccine products at FDA, resigned: they wanted no part of this."
Dr. Vinay Prasad is a hematologist-oncologist and Associate Professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco. He runs the VKPrasad lab at UCSF, which studies cancer drugs, health policy, clinical trials and better decision making. He is author of over 300 academic articles, and the books Ending Medical Reversal (2015), and Malignant (2020).
